Department of Viroscience, Erasmus MC.
J Infect Dis. 2013 Nov 1;208(9):1359-65. doi: 10.1093/infdis/jit350. Epub 2013 Jul 30.
Long-term acyclovir (ACV) prophylaxis, recommended to prevent recurrent herpes simplex virus type 1 (HSV-1) ocular disorders, may pose a risk for ACV-refractory disease due to ACV resistance. We determined the effect of ACV prophylaxis on the prevalence of corneal ACV-resistant (ACV(R)) HSV-1 and clinical consequences thereof in patients with recurrent HSV-1 keratitis (rHK).
Frequencies of ACV(R) viruses were determined in 169 corneal HSV-1 isolates from 78 rHK patients with a history of stromal disease. The isolates' ACV susceptibility profiles were correlated with clinical parameters to identify risk factors predisposing to ACV(R) rHK.
Corneal HSV-1 isolates with >28% ACV(R) viruses were defined as ACV(R) isolates. Forty-four isolates (26%) were ACV-resistant. Multivariate analyses identified long-term ACV prophylaxis (≥12 months) (odds ratio [OR] 3.42; 95% confidence interval [CI], 1.32-8.87) and recurrence duration of ≥45 days (OR 2.23; 95% CI, 1.02-4.87), indicative of ACV-refractory disease, as independent risk factors for ACV(R) isolates. Moreover, a corneal ACV(R) isolate was a risk factor for ACV-refractory disease (OR 2.28; 95% CI, 1.06-4.89).
The data suggest that long-term ACV prophylaxis predisposes to ACV-refractory disease due to the emergence of corneal ACV(R) HSV-1. ACV-susceptibility testing is warranted during follow-up of rHK patients.
阿昔洛韦(ACV)长期预防方案,旨在预防复发性单纯疱疹病毒 1 型(HSV-1)眼部疾病,但由于 ACV 耐药性,可能会导致 ACV 难治性疾病。我们旨在确定 ACV 预防方案对复发性 HSV-1 角膜炎(rHK)患者中角膜 ACV 耐药(ACV(R))HSV-1 流行率及其临床后果的影响。
从 78 例有基质病史的 rHK 患者的 169 例角膜 HSV-1 分离株中确定 ACV(R)病毒的频率。将分离株的 ACV 药敏谱与临床参数相关联,以确定易患 ACV(R) rHK 的危险因素。
将 ACV(R)病毒>28%的角膜 HSV-1 分离株定义为 ACV(R)分离株。44 株(26%)为 ACV 耐药。多变量分析确定了长期 ACV 预防(≥12 个月)(比值比[OR]3.42;95%置信区间[CI]1.32-8.87)和复发持续时间≥45 天(OR 2.23;95%CI1.02-4.87),提示 ACV 难治性疾病,是 ACV(R)分离株的独立危险因素。此外,角膜 ACV(R)分离株是 ACV 难治性疾病的危险因素(OR 2.28;95%CI1.06-4.89)。
数据表明,长期 ACV 预防方案由于角膜 ACV(R) HSV-1 的出现,导致 ACV 难治性疾病的发生。在 rHK 患者的随访中应进行 ACV 药敏试验。